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Prognostic factors in endometrial carcinoma – a single-center study 
 
Prognostički čimbenici kod oboljelih od raka endometrija 
 




Endometrial cancer (EC) is the fourth most common cancer in women in Croatia and the second most 
common gynecological malignancy with the trend of increasement in incidence. The aim of this single-centre 
study was to analyze ECs clinical and pathological characteristics and to assess the correlation between risk 
factors and the reccurence of the disease. We retrospectively reviewed medical records of 174 women that were 
diagnosed with endometrial cancer between January 2011 and May 2015. Among the women that were 
diagnosed ECs in the patohistologic specimen, histologic subtype, grade, cancer stage, depth of myometrial 
tumor invasion, presence of lymph-vascular space involvement (LVSI), lower uterine segment or surface cervical 
glandular involvement were documented. In addition, women’s age, BMI, number of successful deliveries and 
comorbidities (diabetes mellitus and hypertension) were obtained and incorporated in the statistical analysis. We 
demonstrated a strong corellation between higher tumor grade, deeper myometrial invasion, presence of 
lymphovascular space invasion and disease reccurence in our cohort. Due to rapid increasement in incidence, 
further education, increasement of public awareness, measures for prevention, diagnostic procedures and 
advances in therapy are imperative to decrease the overall morbidity and mortality rate. 




Rak endometrija predstavlja četvrti najčešći uzrok maligne bolesti kod žena u Hrvatskoj i ukupno je na 
drugom mjestu po učestalosti ginekoloških maligniteta, s jasno naznačenom tendencijom porasta incidencije 
u budućnosti. Cilj istraživanja bio je analizirati kliničko-patološke čimbenike i njihove uzročno-posljedične 
veze s nastankom recidiva. Retrospektivno smo obradili 174 žene liječene u Klinici za ženske bolesti i porode 
kojima je dijagnosticiran karcinom endometrija u razdoblju od siječnja 2011. do svibnja 2015. godine. 
Analizirali smo histološke nalaze i stadij tumora, stupanj, dubinu invazije miometrija, prisutnost/odsutnost 
limfokapilarne invazije, te invazije strome i donjeg uterinog segmenta. Analizirani su podaci o dobi, indeksu 
tjelesne mase, paritetu i prisutnim komorbiditetima (dijabetes melitus i arterijska hipertenzija). Rezultati 
istraživanja pokazuju da na razvoj recidiva karcinoma endometrija značajno utječu sljedeći prognostički 
čimbenici: dubina invazije tumora, stupanj tumora, limfokapilarna invazija, metastaze u limfnim čvorovima, 
invazija istmusa i invazija cerviksa. 








Endometrial cancer (EC) is the fourth most 
common cancer in women in Croatia and the second 
most common site of gynecologic cancer in women 
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after breast cancer with 659 new cases in Croatia in 
2015 and an overall proportion of 6% among all female 
malignancies.1 The incidence of this tumor tends to 
increase with population aging, obesity and co-
morbidities (e.g. diabetes mellitus and hypertension).2 
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Moreover, the EC incidence is estimated to increase by 
1-2% annually with EC accounting annually for about 
3% of deaths due to cancer.3 
The cornerstone of treatment for most of the newly 
diagnosed women consists of surgery with total 
hysterectomy and bilateral salpingo-oophorectomy, 
complemented with pelvic and paraaortal lympha-
denectomy in selected cases. Contemporary 
management of EC is based on personalized surgical 
and adjuvant treatment. A proper management strategy 
and its implementation is still controversial with 
currently used risk assessment methods. Specifically, 
the issue of lymphadenectomy remains under debate.4 
About 75% of women with EC are diagnosed in the 
early stages and have relatively good survival rates; 
however, women who are diagnosed in advanced-stage 
or have recurrent disease have a poor prognosis.3 
The aim of the present study was to analyze EC 
clinical and pathological characteristics and to assess 
the correlation between these risk factors and 
recurrence development. 
 
Materials and methods 
 
We retrospectively reviewed the medical records of 
174 women with endometrial cancer at the Department 
of Obstetrics and Gynecology, University Hospital 
Centre, Zagreb, Croatia between January 2011 and 
May 2015 following the Institutional Review Board 
approval. Statistical analysis was performed by IBM 
SPSS ver. 20.0 (IBM Corp., Armonk, NY, USA). 
Among the women that were diagnosed with EC in the 
pathophysiologic specimen, histologic subtype, grade, 
cancer stage, depth of myometrial tumor invasion, 
presence of lymphovascular space invasion (LVSI), 
lower uterine segment or surface cervical glandular 
involvement were abstracted. In addition, women’s 
age, BMI, parity and comorbidities (diabetes mellitus 
and arterial hypertension) were obtained and 
incorporated in statistical analysis.  
The presence of diabetes mellitus proven by 
laboratory data (fasting plasma glucose of ≥ 7.0 
mmol/L or haemoglobin A1C levels ≥ 6.5%), obesity 
(BMI, calculated as weight (kg)/[height (m)]2 with 
values ≥ 25 kg/m2) and arterial hypertension (defined 
as office systolic blood pressure values ≥ 140 mmHg 
and/or diastolic blood pressure values ≥ 90 mmHg) 
was obtained by reviewing the patient files.  
Lower uterine segment involvement (LUSI) was 
defined as the presence of tumor invasion in the uterine 
isthmus (a specialized portion of uterus lying between 
the corpus and cervix uteri). The depth of myometrial 
tumor invasion was measured from the endo-
myometrial junction to the deepest point of myometrial 
invasion. The endomyometrial junction refers to the 
transition from endometrium to myometrium. LVSI 
was defined as the presence of viable tumor cells inside 
the endothelium-lined channels of uterine specimens, 
outside the bulk of the invasive tumor.  
Surgical staging was performed using the 
International Federation of Gynecology and Obstetrics 
(FIGO) 2009 classification. 
Descriptive analyses including frequencies, ranges, 
and percentages of variables were conducted for each 
variable in each group. Continuous variables were 
examined for normality by the Kolmogorov-Smirnov 
test expressed with median (range) as appropriate. The 
characteristics and differences between the groups 
were compared using chi-square test for categorical 
variables and using the Mann-Whitney U test for 
continuous variables. The potentially important              
risk factors were tested with stepwise multivariate 
conditional logistic regression analysis to assess its 
positive or negative relationship with the presence of 
disease recurrence. Tumor recurrence was confirmed 
via clinical pelvic exam or imaging study during 
regular clinical assessment. 
The statistical significance was set at P value < 
0.05. For this type of study, a formal consent was not 
required, and the Ethical Committee gave approval to 






During the study period, a total of 174 women were 
diagnosed with endometrial cancer with a median age 
of 62 (range 33-84) years while 71.84% of them had 
comorbidities, as in our study were diabetes mellitus, 
hypertension or/and obesity. FIGO grade distribution 
was as follows: 53.45% were grade 1A, 31.61% were 
grade 1B, 5.75% were grade 2, 0.57% were grade 3A, 
5.75% were grade 3C1 and 2.87% were grade 4B. The 
most common subtype was endometrioid adeno-
carcinoma (95.98%), followed by mucinous adeno-
carcinoma (2.30%) and mixed serous-endometrioid 
carcinoma of the uterus (1.72%).  
Following surgery, 68 women (39.1%) received 
different adjuvant therapy modalities selected from 
brachytherapy, external-beam radiation therapy, 
chemotherapy, or concurrent chemoradiation based on 
the known risk factors evaluated by a gynecologic 
oncologist.  
Disease recurrence was confirmed in an overall of 
18 (10.34%) women. 
Patient characteristics are summarized in Table 1. 
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Table 1 Patients’ characteristics 
Tablica 1 Karakteristike pacijenata 
 
Study group (N = 174) 
Studijska grupa 
 Value / Vrijednost 
(median,               
min.-max.) 
Age at time of diagnosis 
Starost kod dijagnoze 







Parity / Broj poroda   2 (0-6) 
Depth of myometrial invasion (mm) 
Dubina miometrijalne invazije 
 7 (0-21) 
Comorbidities 
Komorbideti 
YES / DA 




















Lymphovascular space invasion (LVSI) 
Invazija limfovascularnog prostora 
YES / DA 
NO / NE 
36 (20.69%) 
138 (79.31%) 
Lymph node involvement 
Zahvaćanje limfnih čvorova 
 
Without dissection / Bez disekcije 
Negative / Negativno 




Lower uterine segment involvement 
Zahvaćanje donjeg segmenta maternice 
Without involvement / Bez 
uključivanja 
Mucosa / Sluznica 
Stroma 
Mucosa and stroma combined/ 






Zahvaćanje vrata maternice 
 
Without involvement / Bez 
uključivanja 
Mucosa / Sluznica 
Stroma 
Mucosa and stroma combined/ 



























YES / DA 





YES / DA 
NO / NE 
18 (10.34%) 
156 (89.66%) 
* 1 = endometrioid adenocarcinoma, 2 = mixed serous-endometrioid carcinoma of the uterus, 3 = mucinous adenocarcinoma 
1 = endometrioidni adenokarcinom, 2 = mješoviti serozno-endometrioidni karcinom maternice, 3 = mucinozni adenokarcinom 
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Univariate and multivariate analysis 
 
Univariate analysis (using disease recurrence as 
main outcome) showed that tumor grade (P = 0,004), 
lymph node involvement (P = 0,023), presence of 
lymph vascular space invasion (P = 0,009), depth of 
stromal tumor invasion (P = 0,001), lower uterine 
segment and cervical involvement (P = 0,024 and P = 
0,030, respectively) had influence (Table 2). 
On multivariate analysis, there was no statistical 
significance due to a relatively small number of disease 
recurrence in cohort (N = 18). 
 
Table 2 Univariate analysis of the association between continouous variables and disease reccurence 
Tablica 2. Univarijantna analiza povezanosti između kontinuiranih varijabli i recidiva bolesti 
 




  YES/DA NO/NE  
Lymph node involvement 
Zahvaćanje limfnih čvorova 
YES/DA 3 (27.27%) 8 (7.02%) 11 
 NO/NE 8 (72.73%) 106 (92.98%) 114 
Total / Sveukupno  11 114 125 
 




  YES/DA NO/NE  
Lymphovascular space invasion (lvsi) 
Invazija imfovaskularnog prostora 
YES/DA 8 (44.44%) 28 (17.95%) 36 
 NO/NE 10 (55.56%) 128 (82.05%) 138 
Total / Sveukupno  18 156 174 
 




  YES/DA NO/NE  
Lower uterine segment involvement 
Zahvaćanje donjeg segmenta maternice 
YES/DA 9 (50%) 39 (25%) 48 
 NO/NE 9 (50%) 117 (75%) 126 
Total / Sveukupno  18 156 174 
 




  YES/DA NO/NE  
 GI 9 (50%) 130 (83.33%) 139 
Grade / Razina GII 6 (33.33%) 18 (11.54%) 24 
 GIII 3 (16.67%) 8 (5.13%) 11 
Total / Sveukupno  18 156 174 
 




  YES/DA NO/NE  
 Without involvement 
Bez zahvaćanja 
11 (61.11%) 131 (84.52%) 142 
Cervical involvement 
Zahvaćanje vrata maternice 
Mucosa involvement 
Zahvaćanje mukoze 
3 (16.67%) 14 (9.03%) 17 
 Stroma involvement 
Zahvaćanje strome 
4 (22.22%) 10 (6.45%) 14 
Total / Sveukupno   18 155 173 
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Discussion and conclusions 
 
The risk factors for endometrial cancer have been 
already described and include obesity, long-term 
estrogen replacement therapy, diabetes mellitus, 
hypertension, nulliparity, infertility or failure to 
ovulate, polycystic ovary syndrome, early age at 
menarche, late age at menopause, and selective-
estrogen receptor modulator (SERM, such as 
tamoxifen, raloxifene) use.5 Comorbidities, especially 
obesity, must be considered in the overall treatment 
strategy because it negatively affects anesthesiologic 
parameters and surgical performance, delivery of 
radiation and chemotherapy, with elevated peri-
operative morbidity.6,7 Approximately 70% of women 
with early stage of endometrial cancer are obese.8 The 
management of risk factors such as obesity, diabetes, 
glucose intolerance, and hypertension is demanding in 
order to minimize the overall risk for EC occurrence. 
Almost three out of four women from our cohort had 
at least one comorbidity, which indicates the 
importance of increasing public awareness and 
adequate prevention. According to one multivariate 
linear regression model, which accounts for the 
expected changes in obesity, hysterectomy rates,               
and cessation, the prediction is that by the year 2030, 
the incidence of endometrial cancer will reach 
approximately 42 cases per 100,000 women, which 
represents a 55% increase in incidence compared to   
the one from 2010.9 Exploring other risk factors, such 
as infertility, metabolic syndrome and usage of 
intrauterine devices, further advancement is necessary 
in the understanding of disease pathogenesis. 
According to clinicopathological studies, several 
prognostic factors have been developed for ECs which 
include: age at diagnosis of EC, size of tumor, depth of 
myometrial invasion, presence or absence of lymph 
vascular space invasion, tumor grade and stage, 
involvement of the lower uterine segment, lymph node 
metastases and others, not analyzed in our study, such 
as the presence of hormone receptors.10  
The median age in our group at the time of 
diagnosis was 62 suggesting that low overall survival 
could be expected since younger women have a better 
prognosis and lower recurrence rate compared to 
women older than 65 years.11 Furthermore, the median 
age of the participants in the present study was equal 
to that found by Chen LM et al.12 
There was a strong correlation between higher 
tumor grade, deeper myometrial invasion, presence of 
lymph vascular space invasion and disease recurrence 
in the present cohort. The median value of myometrial 
invasion in women with disease recurrence was 9 
millimeters, while the median in the group with no 
recurrence detected was 5 millimeters. These findings 
can determine the overall treatment strategy in a great 
part.  
The recurrence rate in our study group was 7.5%            
at early stage EC, which was like recent literature 
findings.13 Most of the women with recurrence of early 
stage EC were symptomatic at diagnosis, with vaginal 
bleeding or abdominal discomfort as a main symptom. 
The overall recurrence rate in our study group was in 
range or even slightly lower compared to available 
literature,14 although an evaluation is necessary in the 
years to come. 
Despite different study designs, the present study 
confirms recent literature findings,10,15,16 extrapolated 
on Croatian population.  
The limitation of our study is in a low number of 
non-endometrioid tumors. In addition, there were not 
enough data concerning death events to analyze the 
overall survival. Prospective evaluation with long-term 
follow-up is needed to draw an accurate conclusion. 
With rapidly increased incidence, further education, 
increase of public awareness, prevention, diagnostic 
and therapeutic advance is imperative to decrease the 
overall morbidity and mortality rate. 
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